

collected from each well and examined on IFN- $\gamma$  by usual enzyme immunoassay. In parallel, a systems as a control using the polypeptide in Reference for that in Example 4-1 or using no polypeptide was treated similarly as above. The results were in Table 1. IFN- $\gamma$  in Table 1 were expressed with international units (IU), calculated based on the IFN- $\gamma$  standard, Gg23-901-530, obtained from the International Institute of Health, USA.--

IN THE CLAIMS

Please cancel non-elected claims 1, 2, 48, 10, 11, 13, 14, and 16 without prejudice to the filing of a divisional application therein.

Please replace claims 3 and 17 as follows below. A marked up version of the amended claims to show the changes made is attached hereto.

3 (Once-amended). A method for treating IFN- $\gamma$  and/or killer cell-susceptive tumors using gene therapy, comprising:  
transforming tumor cells obtained from a subject in need thereof with a composition comprising an isolated DNA molecule that comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:1, where Xaa is isoleucine or threonine, and a carrier capable of introducing the isolated

DNA molecule into a mammalian cell, wherein said nucleotide sequence consists of the sequence of a fragment of human genomic DNA;

proliferating the transformed tumor cells ex vivo;

and

transplanting the proliferated transformed tumor cells into the subject to treat the tumor cells in the subject.

17 (Once-amended). A method for treating IFN- $\gamma$  and/or killer cell-susceptive tumors using gene therapy, comprising:

transforming tumor cells obtained from a subject in need thereof with an isolated DNA molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:1, where Xaa is isoleucine or threonine, wherein said nucleotide sequence consists of the sequence of a fragment of human genomic DNA;

proliferating the transformed tumor cells ex vivo;

and

transplanting the proliferated transformed tumor cells into the subject to treat the tumor cells in the subject.

Please cancel claims 9, 12 and 20 without prejudice and insert claims 18-20 in place thereof as follows:

--18(New). The method according to claim 2, wherein the carrier is a virus or liposome.--

--19(New). The method according to claim 3, wherein the isolated DNA molecule is linked with a heterologous nucleotide sequence.--

--20(New). The method according to claim 19, wherein the heterologous nucleotide sequence is a virus vector.--